Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Dose-escalation Study of MEDI-551 in Japanese Adults With Relapsed or Refractory Advanced B-cell Malignancies
jRCT2080221827Phase 1
- Sponsor
- AstraZeneca
- Start
- Jun 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of inebilizumab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and 2 more, sponsored by AstraZeneca.
02
Drugs
inebilizumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)multiple myeloma (MM)B-cell malignancy
Beyond the preview
Go deeper on jRCT2080221827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221827.